Compare Amphastar Pharmaceuticals Inc (AMPH) vs Halliburton Company (HAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Halliburton Company — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Halliburton Company trades at $34.65 (market cap $28.73B). The key difference: Halliburton Company is far larger — about 34.8× Amphastar Pharmaceuticals Inc's market cap, and Halliburton Company pays a 1.98% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | HAL | |
|---|---|---|
Market Cap | $826.08M | $28.73B |
Sector | Health | Energy |
52-Week High | $30.81 | $42.98 |
52-Week Low | $16.87 | $20.50 |
Enterprise Value | $1.22B | $34.81B |
Dividend Yield | — | 1.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Halliburton (HAL) trades at $34.39, up 0.79% with a bullish technical signal. The company shows solid fundamentals with a P/E of 19 and ROE of 14.56%, though recent earnings beat expectations with Q1 2026 EPS of $0.55 versus $0.50 expected. Recent developments include a key Iraq oilfield deal and digital transformation partnerships, supporting growth prospects in the oil services sector.
Outlook remains positive with analyst consensus price target of $44.00 (28% upside), though risks include oil price volatility and execution challenges. Revenue stability around $22B and strong cash flow generation provide fundamental support, while technical indicators suggest potential resistance near $35.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
